Trial Profile
Post Marketing Surveillance Program of Praxbind Use in India.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Idarucizumab (Primary) ; Dabigatran etexilate
- Indications Blood coagulation disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 25 Feb 2020 Status changed from recruiting to completed.
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.
- 20 Dec 2018 Planned initiation date changed from 10 Dec 2018 to 26 Dec 2018.